Want to join the conversation?
$VRX has appointed Howard B. Schiller as interim CEO to replace Michael Pearson, who is hospitalized. The timing of Pearson's return is uncertain and he will be on medical leave of absence until further notice. The Canadian drugmaker has also announced that Robert Ingram, Lead Independent Director, will serve as Interim Chairman of the BoD.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.